"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 3 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 3 | 6 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 0 | 1 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 2 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
-
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566.
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. Am J Respir Crit Care Med. 2022 05 15; 205(10):1228-1235.
-
Latent Tuberculosis Infection. N Engl J Med. 2021 12 09; 385(24):2271-2280.
-
In vitro elucidation of the crucial but complex oxidative tailoring steps in rufomycin biosynthesis enables one pot conversion of rufomycin B to rufomycin C. Chem Commun (Camb). 2021 Nov 09; 57(89):11795-11798.
-
Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2021 09 17; 65(10):e0179420.
-
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718.
-
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021 02 11; 76(3):582-586.
-
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938.
-
Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. Lancet HIV. 2020 01; 7(1):e27-e37.